Notice of Intent to Publish a Funding Opportunity Announcement for Generate A Precision Medicine Intergenerational Resource for the Study of Factor VIII Immunogenicity in Severe Hemophilia A:Clinical Coordinating Center
ID: 322896Type: Forecasted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $1M

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/322896
Timeline
    Description

    The National Institutes of Health (NIH) is preparing to publish a Funding Opportunity Announcement (FOA) for the establishment of a Clinical Coordinating Center aimed at generating a Precision Medicine Intergenerational Resource for the study of Factor VIII immunogenicity in severe Hemophilia A. This initiative will utilize a UG3/UH3 Exploratory/Developmental Phased Award Cooperative Agreement, allowing for a total of up to seven years of support, contingent upon the successful completion of core milestones over the initial three-year phase and subsequent four-year phase. The funding opportunity, which has an estimated total program funding of $2,060,000 and an award ceiling of $1,338,000, is designed to facilitate the development of a comprehensive resource that will enhance understanding and treatment of severe Hemophilia A. Interested applicants can reach out to Dr. Iman K. Martin at iman.martin@nih.gov or by phone at 301-435-0065 for further information, with the anticipated award date set for January 5, 2021.

    Point(s) of Contact
    Iman K. Martin, PhD, MPH, MS
    (301) 435-0065
    iman.martin@nih.gov
    Files
    No associated files provided.
    Similar Opportunities
    Clinical Coordinating Center for Multi-Site Investigator-Initiated Clinical Trials (Collaborative UG3/UH3 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for the development of a Clinical Coordinating Center (CCC) to support multi-site investigator-initiated clinical trials under the UG3/UH3 activity codes. This initiative aims to foster innovative trial designs relevant to the National Heart, Lung, and Blood Institute's (NHLBI) research mission, requiring comprehensive project plans that address participant recruitment, milestone achievements, and strategies for enhancing community engagement and diversity. The funding mechanism is bi-phasic and necessitates simultaneous applications for both a CCC and a collaborating Data Coordinating Center (DCC), emphasizing strong project management and a commitment to minimizing health disparities. Interested applicants must submit their proposals by September 11, 2025, and can reach out to the NIH OER Webmaster at OERWebmaster03@od.nih.gov for further inquiries. More details can be found in the full announcement at http://grants.nih.gov/grants/guide/pa-files/PAR-22-192.html.
    Enhancing Public Health Surveillance of Bleeding Disorders
    Active
    Centers for Disease Control - NCBDDD
    The Centers for Disease Control and Prevention (CDC) is forecasting a cooperative agreement opportunity titled "Enhancing Public Health Surveillance of Bleeding Disorders." This initiative aims to collect and utilize surveillance data from federally supported hemophilia treatment centers to inform policies and clinical practices related to hemophilia, von Willebrand disease, and other inherited bleeding disorders, ultimately seeking to reduce health complications and improve the quality of life for affected individuals. The program is critical for understanding treatment practices, monitoring health complications, and identifying causes of death among those with bleeding disorders. The estimated total program funding is $21.5 million, with individual awards ranging from $100,000 to $4.3 million. Interested applicants can reach out to Brandi Dupervil at (404) 498-6879 or via email at inm4@cdc.gov, with applications due by May 15, 2025, and an anticipated award date of August 31, 2025.
    Centers for Precision Disease Modeling (U54) (Clinical Trials Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity for the Centers for Precision Disease Modeling (U54), aimed at advancing personalized medicine through the integration of animal genomics with human disease research. This initiative invites applications for cooperative agreements that will support collaborative research projects, enhancing preclinical studies by utilizing precision animal models to evaluate disease-causing variants. The program emphasizes the importance of bridging laboratory research with clinical applications to improve patient care, with each application eligible for funding up to $1,250,000 annually over a maximum project period of five years. Proposals are due by December 15, 2024, and interested applicants can find more information by contacting NIH Grants Information at grantsinfo@nih.gov or visiting the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-24-305.html.
    NIAMS Clinical Trial Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity for the NIAMS Clinical Trial Implementation Cooperative Agreement (UG3/UH3), aimed at supporting interventional clinical trials focused on rheumatic, musculoskeletal, and skin diseases. This initiative encompasses a two-phase approach, where the UG3 phase involves trial preparation and the UH3 phase focuses on trial execution, contingent upon meeting specific milestones. The program emphasizes the importance of developing clinical protocols, obtaining IRB approval, and securing necessary resources, while also promoting health equity by engaging individuals with lived experience in the research process. Interested applicants can apply for funding up to $250,000 for the UG3 phase, with a closing date for submissions set for March 4, 2027. For further inquiries, applicants may contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-24-208.html.
    NIAID Clinical Trial Implementation Cooperative Agreement (U01 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a Notice of Funding Opportunity (NOFO) for the NIAID Clinical Trial Implementation Cooperative Agreement (U01), aimed at supporting high-risk clinical trials that enhance the understanding of human diseases. This funding opportunity encourages applications for investigator-initiated, milestone-driven clinical trials, with each application permitted to propose only one clinical trial that must demonstrate a hypothesis-driven approach. The initiative emphasizes the importance of mechanistic studies within clinical trials and requires a robust plan for managing trial complexity and participant safety. Interested applicants can find additional details and guidelines at the provided NIH link, with the earliest submission date set for April 12, 2024, and the application deadline on January 13, 2027. For inquiries, applicants may contact NIH Grants Information at grantsinfo@nih.gov.
    Notice of Intent to Publish a Funding Opportunity Announcement for Somatic Cell Genome Editing Translational Coordination and Dissemination Center (U24, Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is forecasting a funding opportunity for the establishment of a Somatic Cell Genome Editing Translational Coordination and Dissemination Center (TCDC) as part of its Somatic Cell Genome Editing (SCGE) program. The objective of this initiative is to accelerate the development of genome editing therapeutic agents by facilitating Investigational New Drug (IND) application enabling studies, establishing regulatory approval pathways, and disseminating successful strategies for initiating first-in-human clinical trials. This funding opportunity is crucial for advancing innovative therapeutic approaches in health, with an estimated total program funding of $2 million and the expectation of one award. Interested applicants can reach out to Dr. Marrah Lachowicz-Scroggins at SCGEprogram@od.nih.gov or by phone at 301-827-8229 for further details, with the anticipated application due dates in Summer 2022 and an estimated award date of April 1, 2023.
    Notice of Intent to Publish a Funding Opportunity Announcement for Data Management and Coordinating Center (DMCC) for Rare Diseases Clinical Research Network (RDCRN) (U2C Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) plans to publish a Funding Opportunity Announcement (FOA) for the establishment of a Data Management and Coordinating Center (DMCC) as part of the Rare Diseases Clinical Research Network (RDCRN). This initiative aims to enhance the diagnosis, management, and treatment of rare diseases by facilitating collaborative, multi-site, patient-centric research through the RDCRN and supporting the activities of the Rare Diseases Clinical Research Consortia (RDCRC). The estimated total program funding for this grant is $1,000,000, with the FOA expected to be published in 2024 and awards anticipated in 2025. Interested applicants can reach out to Dr. Tiina K. Urv at urvtiin@mail.nih.gov or by phone at 301-827-2746 for further information.
    Notice of Intent to Publish a Notice of Funding Opportunity (NOFO) for the Rare Diseases Clinical Research Consortia (RDCRC) for the Rare Diseases Clinical Research Network (RDCRN)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Notice of Funding Opportunity (NOFO) for the Rare Diseases Clinical Research Consortia (RDCRC) as part of the Rare Diseases Clinical Research Network (RDCRN). This initiative aims to solicit applications for collaborative, multi-site research focused on advancing the diagnosis, management, and treatment of rare diseases, with an emphasis on addressing unmet clinical trial readiness needs. The funding, estimated at $1 million, will support specialized centers through cooperative agreements, with the NOFO expected to be published in winter 2024 and applications due in summer 2024. Interested applicants should prepare to develop meaningful collaborations, as the estimated award date is set for July 1, 2025.
    Notice of Intent to Publish a Funding Opportunity Announcement for the Rare Diseases Clinical Research Consortia (RDCRC) for the Rare Diseases Clinical Research Network (RDCRN)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) plans to publish a Funding Opportunity Announcement (FOA) for the Rare Diseases Clinical Research Consortia (RDCRC) as part of the Rare Diseases Clinical Research Network (RDCRN). This initiative aims to enhance the diagnosis, management, and treatment of rare diseases through collaborative, multi-site, patient-centric research, with a focus on addressing unmet clinical trial readiness needs. The estimated total program funding for this opportunity is $1,000,000, with the FOA expected to be published in 2024 and applications due later that year. Interested applicants can reach out to Dr. Tiina K. Urv at 301-827-2746 or via email at urvtiin@mail.nih.gov for further information.
    Notice of Intent to Publish a Funding Opportunity Announcement for Limited Competition for the Continuation of Clinical Sites for the Undiagnosed Diseases Network (U01 - Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Funding Opportunity Announcement (FOA) for a Limited Competition aimed at continuing the support for Clinical Sites within the Undiagnosed Diseases Network (UDN). This initiative is specifically designed for institutions and Program Directors/Principal Investigators who have previously received NIH funding under the UDN program, allowing them to compete for an additional year of funding to enhance their participation, establish collaborations, and develop sustainability plans as the network transitions into a national resource. The total estimated program funding is $6.5 million, with an award ceiling of $400,000 and an expected 11 awards to be made. Interested applicants should note that the FOA is anticipated to be published in August 2022, with applications due by September 2022. For further inquiries, potential applicants can contact Dr. Argenia Doss at argenia.doss@nih.gov or by phone at 301-827-1373.